GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Use of Recombinant Factor VIIa (NovoSeven) for
Treatment of Active Or Impending Bleeding in
Brain Injury: Broadening the Indications

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&l...

>>
J Clin Anesth. 2006 Nov;18(7):545-51.

Yusim Y, Perel A, Berkenstadt H, Attia M, Knoller N, Sidi A.

Department of Anesthesiology, Sheba Medical Center, Tel-Hashomer 52621, Israel.

We report three patients with severe traumatic brain injury, both open and closed, who were treated with recombinant activated factor VII. This treatment was given in a desperate, last-ditch effort to save the life of patient 1, as a preventive or early treatment of a developing hematoma in patient 2, and as treatment of a threatening hematoma in patient 3. One of the three patients survived.

During the past few years we have broadened the indications for recombinant activated factor VII and started using it as a preventive measure rather than as a "last line of defense." However, the potential complications of disseminated intravascular coagulation and thrombotic events, as well as the cost-effectiveness in view of the available evidence-based medicine, should be considered.
<<